Abstract
Introduction: The N2 /IIIA Non small cell Lung cancer is a heterogenous group of patients with many differences within the stage that warrant different treatment strategies and have an individual prognosis that varies depending on the size, site and number of lymph node stations involved. Method: Review of the pertinent current literature on the identification of the various subsets of N2 disease and their management and prognosis. Discussion: Define the spectrum of N2 disease and characterize the subsets within the stage. Highlight the different management strategies and prognosis of the various N2 scenarios that are commonly seen. Examine the evidence for restaging after neoadjuvant therapy and the modalities that may be used. Summary: A concise outline of the subsets within the N2/IIIA stage with their evidence based treatment and survival.
Keywords: Ipsilateral mediastinal lymph node, positron emission tomography, Computed tomography scanning, endoscopic ultrasound, N2 Disease, Platinum-based therapy
Current Cancer Therapy Reviews
Title: Stage N2/IIIA Non Small Cell Lung Cancer: An Evidence-Based Review
Volume: 3 Issue: 2
Author(s): Christopher B. Komanapalli, Charles R. Thomas and Mithran S. Sukumar
Affiliation:
Keywords: Ipsilateral mediastinal lymph node, positron emission tomography, Computed tomography scanning, endoscopic ultrasound, N2 Disease, Platinum-based therapy
Abstract: Introduction: The N2 /IIIA Non small cell Lung cancer is a heterogenous group of patients with many differences within the stage that warrant different treatment strategies and have an individual prognosis that varies depending on the size, site and number of lymph node stations involved. Method: Review of the pertinent current literature on the identification of the various subsets of N2 disease and their management and prognosis. Discussion: Define the spectrum of N2 disease and characterize the subsets within the stage. Highlight the different management strategies and prognosis of the various N2 scenarios that are commonly seen. Examine the evidence for restaging after neoadjuvant therapy and the modalities that may be used. Summary: A concise outline of the subsets within the N2/IIIA stage with their evidence based treatment and survival.
Export Options
About this article
Cite this article as:
Komanapalli B. Christopher, Thomas R. Charles and Sukumar S. Mithran, Stage N2/IIIA Non Small Cell Lung Cancer: An Evidence-Based Review, Current Cancer Therapy Reviews 2007; 3 (2) . https://dx.doi.org/10.2174/157339407780618416
DOI https://dx.doi.org/10.2174/157339407780618416 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences The Co-regulatory Role of 5-Lipoxygenase and Cyclooxygenase-2 in the Carcinogenesis and their Promotion by Cigarette Smoking in Colons
Current Medicinal Chemistry Tumor-Derived Extracellular Fragments of Receptor Protein Tyrosine Phosphatases (RPTPs) as Cancer Molecular Diagnostic Tools
Anti-Cancer Agents in Medicinal Chemistry Cholinergic Receptors as Target for Cancer Therapy in a Systems Medicine Perspective
Current Molecular Medicine Synthesis of Xanthones and Benzophenones as Inhibitors of Tumor Cell Growth
Letters in Drug Design & Discovery Parallel Gene Expression Profiling of Mantle Cell Lymphoma – How Do We Transform ´Omics Data into Clinical Practice
Current Genomics Herb-drug Interactions Involving Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism The Combination of FDG PET/CT and Contrast Enhanced CT in the Evaluation of Recurrent Pancreatic Carcinoma and Cholangiocarcinoma
Current Medical Imaging Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope
Reviews on Recent Clinical Trials Assessment of Airway Inflammation by Exhaled Breath Condensate and Impedance Due to Gastroesophageal Reflux Disease (GERD)
Inflammation & Allergy - Drug Targets (Discontinued) Phosphoproteomics as a Promising Tool for Broadening the Analysis of Clinical Samples and for the Fight Against Cancer Disease
Current Pharmaceutical Analysis Metabolomics of Serum Peptides
Protein & Peptide Letters Intracellular Trafficking of MDR Transporters and Relevance of SNPs
Current Topics in Medicinal Chemistry Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials Histone Deacetylase Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry The Role of TNFSF15 in the Modulation of Neovascularization and Inflammation
Current Hypertension Reviews Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets To Be, or Not To Be: That is the Question-Lineage Commitment in Hematopoiesis
Current Immunology Reviews (Discontinued)